Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 10: - Darth Vaper strikes again
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Which is part of the criteria for treatment-resistant schizophrenia (TRS)?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 167 - 182Publisher: Cambridge University PressPrint publication year: 2024
References
Asenjo Lobos, C, Komossa, K, Rummel-Kluge, C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; CD006633CrossRefGoogle Scholar
Bozzatello, P, Bellino, S, Rocca, P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Front Psychiatry 2019; 10:67CrossRefGoogle ScholarPubMed
Demjaha, A, Lappin, JM, Stahl, D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017; 47:1981–9CrossRefGoogle ScholarPubMed
Gillespie, AL, Samanaite, R, Mill, J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017; 17:12CrossRefGoogle ScholarPubMed
Glasser, AM, Collins, L, Pearson, JL, et al. Overview of Electronic Nicotine Delivery Systems: a systematic review. Am J Prev Med 2017; 52:e33–e66CrossRefGoogle ScholarPubMed
Granfors, MT, Backman, JT, Laitila, J, et al. Oral contraceptives containing ethinylestradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005; 78:400–11CrossRefGoogle ScholarPubMed
Grover, S, Sahoo, S, Rabha, A, et al. ECT in schizophrenia: a review of the evidence. Acta Neuropsychiatr 2019; 31:115–27CrossRefGoogle ScholarPubMed
Howes, OD, McCutcheon, R, Agid, O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174:216–29CrossRefGoogle Scholar
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Focus (Am Psychiatr Publ) 2020; 18:443–55Google ScholarPubMed
Kane, J, Honigfeld, G, Singer, J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–96CrossRefGoogle ScholarPubMed
Keepers, GA, Fochtmann, LJ, Anzia, JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020; 177:868–72CrossRefGoogle ScholarPubMed
Lally, J, Ajnakina, O, Di Forti, M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016; 46:3231–40CrossRefGoogle ScholarPubMed
Marder, SR, Yang, YS. Clozapine. In Schatzberg, AF, Nemeroff, CB, eds. The American Psychiatric Association Publishing Textbook of Psychopharmacology. Arlington, VA: American Psychiatric Publishing, Inc. 2017.Google Scholar
McEvoy, JP, Lieberman, JA, Stroup, TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600–10CrossRefGoogle Scholar
Meyer, JM, Stahl, SM. The Therapeutic Threshold and the Point of Futility. Cambridge: Cambridge University Press, 2021, 34–59Google Scholar
Meltzer, HY, Alphs, L, Green, AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82–91CrossRefGoogle ScholarPubMed
Meyer, JM, Stahl, SM. The Clozapine Handbook: Stahl’s Handbooks. Cambridge: Cambridge University Press, 2019CrossRefGoogle Scholar
Prior, TI, Baker, GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28:99–112Google ScholarPubMed
Saffari, AA, Daher, N, Ruprecht, AA, et al. Particulate metals and organic compounds from electronic and tobacco-containing cigarettes: comparison of emission rates and secondhand exposure. Environ Sci Process Impacts 2014; 16(10):2259–67CrossRefGoogle ScholarPubMed
Schatzberg, A, Nemeroff, C. The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5. Arlington, VA: American Psychiatric Publishing, Inc., 2017CrossRefGoogle Scholar
Sinclair, DJM, Zhao, S, Qi, F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Schizophr Bull 2019; 45:730–2CrossRefGoogle ScholarPubMed
Singh, H, Dubin, WR, Kaur, S. Drug interactions affecting clozapine levels. J Psychiatr Intensive Care 2015; 11:52–65CrossRefGoogle Scholar
Smith, T, Mican, L. What to do when your patient who takes clozapine enters a smoke-free facility. Curr Psychiatry 2014; 13:47–8, 57Google Scholar
Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Swainston Harrison, T, Perry, CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64:1715–36CrossRefGoogle ScholarPubMed
Taylor, D, Paton, C, Kapur, S. The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. Chichester: Wiley-Blackwell, 2012Google Scholar
Tiihonen, J, Taipale, H, Mehtälä, J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76:499–507CrossRefGoogle ScholarPubMed
Tiihonen, J, Vartiainen, H, Hakola, P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28:26–8CrossRefGoogle ScholarPubMed
Tsuda, Y, Saruwatari, J, Yasui-Furukori, N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 2014; 4:e004216CrossRefGoogle ScholarPubMed
Vermeulen, JM, van Rooijen, G, van de Kerkhof, MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull 2019; 45:315–29CrossRefGoogle ScholarPubMed
Wagner, E, Löhrs, L, Siskind, D, et al. Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019; 33:423–35CrossRefGoogle ScholarPubMed
Wagner, E, McMahon, L, Falkai, P, et al. Impact of smoking behavior on clozapine blood levels – a systematic review and meta-analysis. Acta Psychiatr Scand 2020; 142:456–66CrossRefGoogle Scholar
Wang, G, Zheng, W, Li, XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res 2018; 105:23–32CrossRefGoogle ScholarPubMed
Youn, T, Jeong, SH, Kim, YS, et al. Long-term clinical efficacy of maintenance electroconvulsive therapy in patients with treatment-resistant schizophrenia on clozapine. Psychiatry Res 2019; 273:759–66CrossRefGoogle ScholarPubMed